Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR | Market Cap | 4.13B +61.6% |
| Revenue (ttm) | 743.48M -2.7% |
| Net Income | 140.44M +2.6% |
| EPS | 2.75 +2.7% |
| Shares Out | 51.15M |
| PE Ratio | 29.39 |
| Forward PE | 27.67 |
| Dividend | 0.94 (1.15%) |
| Ex-Dividend Date | Jul 14, 2025 |
| Volume | 52,963 |
| Average Volume | 96,081 |
| Open | 80.35 |
| Previous Close | 80.70 |
| Day's Range | 78.40 - 80.35 |
| 52-Week Range | 50.05 - 86.70 |
| Beta | 0.33 |
| RSI | 37.62 |
| Earnings Date | May 6, 2026 |
About BME:ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr... [Read more]
Full Company ProfileFinancial Performance
In 2025, BME:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.
Financial StatementsNews
Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ...
Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
Q4 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript
Q4 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q4 2025
2025 saw resilient performance with revenue of EUR 756.1 million and EBITDA up 4%, driven by Specialty Pharma growth and cost efficiencies, despite a CDMO sales decline. 2026 guidance targets high single- to low double-digit revenue growth, with major investments and R&D ramp-up planned.
Laboratorios Farmaceuticos Rovi Transcript: Investor Update
A major U.S. manufacturing site acquisition adds advanced injectable capacity, a five-year $50 million annual contract with BMS, and significant expansion potential. The site will initially operate at cost-neutral levels, with profitability expected as new customers are secured and a new PFS line comes online.
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q2 2025
H1 2025 saw a 4% revenue decline due to weaker CDMO, but specialty pharma sales rose 13% and Okedi sales surged 115%. Gross margin improved to 62.4%, and guidance for 2025 is reiterated, with continued investment in R&D and CDMO capacity.
Laboratorios Farmaceuticos Rovi Transcript: CMD 2025
Rovi outlined a multi-year growth strategy centered on CDMO expansion, Specialty Pharma innovation, and ISM technology, targeting €1.15–1.3 billion in revenues and doubled CDMO sales by 2030. Investments in capacity, new products, and R&D underpin long-term operational leverage and margin growth.
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating ...
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q4 2024
2024 saw a 7.9% revenue decline due to lower COVID-19 vaccine manufacturing, but specialty pharma grew 2% with Okedi sales doubling. Investments in CDMO capacity and new product launches set the stage for future growth, while 2025 revenue is expected to decline mid-single digits.
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q3 2024
Operating revenue fell 5% to EUR 564.6 million due to lower CDMO sales, while specialty pharma grew 1% led by Okedi and Bemiparin. Guidance for 2024 and 2025 anticipates mid-single-digit revenue declines, with focus on European Okedi, CDMO expansion, and R&D investment.
Laboratorios Farmaceuticos Rovi Earnings Call Transcript: Q2 2024
Operating revenue fell 14% in H1 2024 due to lower COVID-19 vaccine manufacturing, while specialty pharma sales grew 1% and Okedi sales surged 141%. EBITDA dropped 28%, but gross margin improved to 59.4%. Full-year revenue is expected to decline mid-single digits.